But, but, but… India’s obesity problem is no small fry, and Big Pharma is racing to cash in. With Eli Lilly launching Mounjaro ahead of Novo Nordisk’s Wegovy, weight-loss drugs are heating up the market.
Meanwhile, PM Modi has waved the red flag on India’s rising obesity crisis— 440 million people could be obese by 2050! This is “huge and scary.” With the economic burden projected to hit a staggering $838.6 billion by 2060 eating up 2.5% of India’s GDP. Is India ready for the weight-loss drug wave?
At the same time, India’s weight-loss drug market is booming, growing at over 30% CAGR over the past five years to nearly Rs 600 crore. With over 100 million obese adults and 101 million diabetics, global pharmaceutical giants see India as the next big battleground for weight-loss treatments.
Lilly’s Mounjaro enters the race, beating Novo Nordisk
In a significant move, U.S.-based Eli Lilly has launched Mounjaro (tirzepatide) in India, becoming the first major player to introduce a GLP-1 weight-loss drug in the country.
Mounjaro, a once-weekly injection approved by India’s drug regulator, is priced at 4,375 rupees for a 5 mg vial and 3,500 rupees for a 2.5 mg vial, its lowest doses, the company told. Its highest dose is 15 mg.A 2 mg weekly dose could cost a patient around Rs 14,000 and a 5 mg weekly dose could cost around Rs 16,500 per month, making it a premium product in India.This puts Novo Nordisk, the Danish drugmaker behind Wegovy and Ozempic, under pressure.
Reportedly, Novo had initially planned to launch Wegovy in India by 2026, but its India team is now pushing for an early 2025 launch. As per Reuters, the company has already secured approval for Wegovy in India but has yet to announce an official launch date.
The pricing puzzle: Global giants vs Local generics
While Mounjaro costs $1,086 per month in the U.S., its Indian pricing is significantly lower. However, some analysts believe it’s still too expensive for most Indian consumers.
Meanwhile, India’s local pharma giants—Sun Pharma, Cipla, Dr. Reddy’s, and Lupin are racing to develop generic versions of these blockbuster drugs. Wegovy’s active ingredient, semaglutide, is expected to go off-patent in India by 2026, opening the floodgates for affordable alternatives.
Obesity, diabetes, and a healthcare time bomb
With obesity and type 2 diabetes rates skyrocketing, India is at a tipping point. According to the International Diabetes Federation, the number of Indian adults with diabetes is expected to surge from 74.2 million in 2021 to over 124 million by 2045.
Government data shows that 24% of women and 23% of men aged 15-49 were overweight or obese between 2019-2021, a sharp rise from the previous decade. The Economic Survey 2023-24 has already flagged obesity as a key health challenge, warning that India’s demographic dividend could be at risk if fitness levels don’t improve.
The future of India’s weight-loss drug market
With a $150 billion global market up for grabs, India is set to become a key battleground for weight-loss drugs. Lilly’s first-mover advantage gives it a head start, but Novo Nordisk’s aggressive push and upcoming local generics could shake up the market.
As weight-loss drugs become more accessible, the real challenge remains – Can India curb its obesity crisis before it spirals into an economic disaster?
